APRISO (mesalamine extended-release capsules) is an aminosalicylate, and symptoms of salicylate toxicity include hematemesis, tachypnea, hyperpnea, tinnitus, deafness, lethargy, seizures, confusion, or dyspnea. Severe intoxication may lead to electrolyte and blood pH imbalance and potentially to other organ (e.g., renal and liver) involvement. There is no specific antidote for mesalamine overdose; however, conventional therapy for salicylate toxicity may be beneficial in the event of acute overdosage. This includes prevention of further gastrointestinal tract absorption by emesis and, if necessary, by gastric lavage. Fluid and electrolyte imbalance should be corrected by the administration of appropriate intravenous therapy. Adequate renal function should be maintained. APRISO (mesalamine extended-release capsules) is a pHdependent delayed-release product and this factor should be considered when treating a suspected overdose.

APRISO (mesalamine extended-release capsules) is contraindicated in patients with hypersensitivity to salicylates or aminosalicylates or to any of the components of APRISO (mesalamine extended-release capsules) capsules.

Last reviewed on RxList: 9/14/2009
This monograph has been modified to include the generic and brand name in many instances.